Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sutacimig

Bispecific antibody · developed by Hemab ApS

Phase 2 Most advanced trial

COAG Developer

1 Registered trials

What is Sutacimig?

Sutacimig is a subcutaneously administered bispecific antibody being developed as a prophylactic treatment for congenital bleeding disorders.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Therapy area: Hematology
Developer: Hemab ApS (COAG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 2QP8468SQP

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07347249	Phase 2	Congenital Factor VII Deficiency	Recruiting	COAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Congenital Factor VII Deficiency

More from Hemab ApS

HMB-001 Phase 1/2 HMB-002 Phase 1/2 HMB-003 Phase 1

Sources

ClinicalTrials.gov NCT07347249

Updated Oct 11, 2026. Something wrong or missing? Report it on the COAG page.

Follow COAG, the company behind Sutacimig

See COAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

COAG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z